EVENTS359
ARTICLES209
CATEGORYMedical
Active
New drug approvals and regulatory decisions from the FDA. Includes NDA approvals, breakthrough therapy designations, and complete response letters.
LATEST EVENTS
| Entity | Type | Summary | Impact | Confidence |
|---|---|---|---|---|
| FDA | regulatory | The FDA released new guidance on expedited programs for serious conditions, including breakthrough product designation. | high | 100% |
| Pharmaceutical Industry | announcement | GoodRx forecasts several novel drugs and new uses for existing medications may receive FDA approval in 2026. | medium | 90% |
| FDA | regulatory | Research found that pivotal trials supporting FDA approvals for Breakthrough Therapy drugs often lack randomization, dou… | medium | 95% |
| Anaphylm (epinephrine film) | regulatory | Anaphylm (epinephrine film) is anticipated to receive first-time FDA approval in 2026. | high | 90% |
| ensitrelvir | regulatory | Ensitrelvir is anticipated to receive first-time FDA approval in 2026. | high | 90% |
| CagriSema (cagrilintide / semaglutide) | regulatory | CagriSema (cagrilintide / semaglutide) is anticipated to receive first-time FDA approval in 2026. | high | 90% |
| Saphnelo (anifrolumab) | regulatory | Saphnelo (anifrolumab) is anticipated to receive FDA approval for new uses, populations, or doses in 2026. | medium | 90% |
| Afrezza (inhaled insulin) | regulatory | Afrezza (inhaled insulin) is anticipated to receive FDA approval for new uses, populations, or doses in 2026. | medium | 90% |
| Wegovy (semaglutide) | regulatory | Wegovy (semaglutide) is anticipated to receive FDA approval for new uses, populations, or doses in 2026. | medium | 90% |
| Shionogi | announcement | GoodRx anticipates potential first-time FDA approval for Shionogi's ensitrelvir in 2026. | medium | 90% |
| AstraZeneca | announcement | GoodRx predicts potential FDA approval for new uses of AstraZeneca's Saphnelo (anifrolumab) in 2026. | medium | 90% |
| MannKind Corporation | announcement | GoodRx forecasts potential FDA approval for new uses of MannKind Corporation's Afrezza (inhaled insulin) in 2026. | medium | 90% |
| Aquestive Therapeutics | announcement | GoodRx anticipates potential first-time FDA approval for Aquestive Therapeutics' Anaphylm (epinephrine film) in 2026. | medium | 90% |
| Novo Nordisk | announcement | GoodRx predicts potential FDA approval for Novo Nordisk's Wegovy (new uses) and CagriSema (first-time) in 2026. | medium | 90% |
| FDA | regulatory | The FDA established a new Breakthrough Drug Category, impacting drug development and patient access to innovative therap… | high | 90% |
| Synerg Biopharma | announcement | Synerg Biopharma published a blog post detailing the typical FDA approval timeline for drugs after completing Phase 3 cl… | low | 80% |
| FDA | regulatory | A Jefferies report indicates nearly 75% of FDA Breakthrough Designated Drugs, particularly for rare diseases and cancer,… | medium | 95% |
| Merck | regulatory | FDA granted Breakthrough Therapy Designation to Merck's Keytruda for treating specific non-small cell lung cancer. | high | 98% |
| FDA | regulatory | FDA introduces new draft guidance for accelerated approvals, imposing stricter requirements for oncology drug developmen… | high | 95% |
| Harvard University | regulatory | Harvard University published research analyzing the FDA's Breakthrough Therapy Designation as a regulatory incentive for… | low | 90% |
WATCHER CONFIG
query: FDA drug approval NDA breakthrough therapy designation regulatory decision
event_types: ['regulatory', 'product', 'announcement']
impact_floor: all
time_window: 7
Signal event details
FDA Drug Approvals
FIELD DATA
RAW DATA